Led by Arun Sanyal, M.D., of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, and Philip Newsome, Ph.D., of Kings College London, researchers are exploring the potential of semaglutide to treat people with metabolic dysfunction-associated steatohepatitis, or MASH
The result is an increased energy expenditure
Contact your GP urgently if you experience severe abdominal pain (potential pancreatitis), persistent vomiting, or signs of gallbladder disease
Gastrointestinal symptoms are the most common manifestations of tirzepatide overdose and may include: Severe nausea and vomiting : Often persistent and more intense than typical side effects, potentially leading to inability to retain fluids or medications Abdominal pain or cramping : May range from mild discomfort to severe pain, typically in the upper abdomen Diarrhea : Can contribute to dehydration and electrolyte imbalances Loss of appetite : Complete aversion to food, extending beyond normal appetite suppression Metabolic disturbances requiring medical attention: Hypoglycemia : Symptoms include trembling, sweating, rapid heartbeat, confusion, dizziness, hunger, irritability, and in severe cases, loss of consciousness or seizures
Here are the most common problems researchers encounter at the 7.5 mg dose and how to address them
